SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MYGN

Myriad Genetics Inc (NASDAQ:MYGN)

US · Delayed Price · Currency is USD
Also listed: 0K3W.LHealthcare · Medical - Diagnostics & Research
$5.46-$0.08 (-1.44%)
 
Market cap
$524M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 6, 1995
Website
Market Cap$523.74M-29.4%
Revenue (ttm)$803.60M-2.6%
Net Income-$129.10M+67.8%
EPS-$1.36+68.5%
Shares Out95.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateJul 1, 2009
Volume1,248,545
Open$5.45
Previous Close$5.54
Day's Range$5.31 - $5.57
52-Week Range$2.74 - $8.09
Beta1.61
AnalystsHold
Price Target$5.42(-0.73%)
Earnings DateFeb 22, 2027

About MYGN

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Address
322 North 2200 West, Salt Lake City, UT, 84116, US
Market Cap
524 million
Employees
2,700
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$101.15K
Bought
$27.68K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
1 Buy4 Hold1 SellAvg target $6.00 (+9.9%)

6 firms rating MYGN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From MYGN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.44%
5 Days
-2.33%
1 Month
-5.21%
6 Months
+42.93%
1 Year
-29.37%

$MYGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MYGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MYGN's directors and management

Net Shares Purchased by Insiders−8k−4k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MYGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MYGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MYGN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MYGN

XBIState Street SPDR S&P Biotech ETF$16.09M
VTIVanguard Morningstar Total Stock Market ETF$14.42M
IWMiShares Russell 2000 ETF$13.54M
VXFVanguard Extended Market ETF$6.62M
IWNiShares Russell 2000 Value ETF$4.89M
FESMFidelity Enhanced Small Cap ETF$4.06M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MYGN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
48.59
Analyst Ratings
40% of score
53
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
2
Buy Value
$27.68K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF1.01%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.57%
GNOMGlobal X - Genomics & Biotechnology ETF0.38%
SQLVRoyce Quant Small-Cap Quality Value ETF0.31%
DMRSDeltaShares S&P 600 Managed Risk ETF0.28%
HAPSHarbor Human Capital Factor US Small Cap ETF0.27%
SLYSPDR S&P 600 Small Cap ETF0.18%
XBIState Street SPDR S&P Biotech ETF0.16%
PQSVPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF0.13%
CAUV.TOAvantis CIBC U.S. Small Cap Value ETF0.11%
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF0.09%
VFVAVanguard U.S. Value Factor ETF0.08%

Weight is the stock’s share of each fund’s holdings.